2019 ESC/EAS Guidelines for the Management of Dyslipidaemias Discussion with Lale Tokgözoğlu and Jeanine Roeters van Lennep
Fotios Barkas, Assistant Professor of Internal Medicine University of Ioannina, shared a noteworthy post on LinkedIn:
“Curious about what happened when the EAS Young Fellows took the mic and interviewed the experts behind the Focused Update on Dyslipidemia Guidelines?
A huge thank you to Lale Tokgözoğlu & Jeanine Roeters van Lennep for this fantastic discussion highlighting the key updates and addressing real-world clinical questions we all face daily!
Maria Cherska thank you for co-hosting this fantastic interview!
Don’t miss it — enjoy!
- Spotify
- Apple Podcasts
- YouTube”
Quoting European Atherosclerosis Society’s post:
“This episode explores the 2025 Focused Update of the 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias, highlighting key changes in cardiovascular risk assessment, LDL-C targets, Lp(a) interpretation, and lipid-lowering strategies. Listeners gain practical insights into how these updates impact everyday clinical decision-making and the future of dyslipidaemia management.
- Spotify
- Apple Podcasts
- Youtube”

Stay updated with Hemostasis Today.
-
May 6, 2026, 11:50Natalie L. Baggio: A 24/7 Neurointerventional Stroke Care at Corewell Health Is Now a Reality
-
May 6, 2026, 11:30Paula Caporal: Consensus on the Diagnosis and Management of Pediatric Stroke in Argentina
-
May 6, 2026, 11:14Li Khim Kwah: Proud for the Development of The New Singapore Stroke Rehabilitation Guideline
-
May 6, 2026, 10:55Hugo Antonio Romo Rubio: A New Paradigm in Treatment for Hemophilia A from FRONTIERS2 Phase 3 Study
-
May 6, 2026, 10:40Ifeanyichukwu Ifechidere: Why INR Can Be Dangerously Misleading
-
May 6, 2026, 02:58Limiaa Babikir: What Is Polyspecific DAT?
-
May 6, 2026, 02:47Karen Rollinson: Connecting with so Many Families and Advocates at HFA 2026
-
May 6, 2026, 02:38Moustafa Abdou: Is the Bone Marrow Examination Still the ‘Gold Standard’?
-
May 6, 2026, 02:23Khaled Musallam: When the Worlds of Thalassemia and Hemophilia Converge